PortfoliosLab logoPortfoliosLab logo
MNTK vs. BEAM
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Performance

MNTK vs. BEAM - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Montauk Renewables, Inc. (MNTK) and Beam Therapeutics Inc. (BEAM). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

MNTK vs. BEAM - Yearly Performance Comparison


2026 (YTD)20252024202320222021
MNTK
Montauk Renewables, Inc.
-31.14%-58.04%-55.33%-19.22%7.61%-12.62%
BEAM
Beam Therapeutics Inc.
-14.03%11.77%-8.89%-30.40%-50.92%-19.92%

Fundamentals

Market Cap

MNTK:

$164.54M

BEAM:

$2.50B

EPS

MNTK:

$0.01

BEAM:

-$0.78

PS Ratio

MNTK:

0.37

BEAM:

95.90

PB Ratio

MNTK:

0.63

BEAM:

2.02

Total Revenue (TTM)

MNTK:

$439.70M

BEAM:

$25.63M

Gross Profit (TTM)

MNTK:

$99.96M

BEAM:

-$284.71M

EBITDA (TTM)

MNTK:

$54.09M

BEAM:

-$352.98M

Returns By Period

In the year-to-date period, MNTK achieves a -31.14% return, which is significantly lower than BEAM's -14.03% return.


MNTK

1D
-3.36%
1M
-25.32%
YTD
-31.14%
6M
-42.79%
1Y
-44.98%
3Y*
-47.33%
5Y*
-37.56%
10Y*

BEAM

1D
8.81%
1M
-16.27%
YTD
-14.03%
6M
-1.81%
1Y
22.02%
3Y*
-8.02%
5Y*
-21.46%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

MNTK vs. BEAM — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

MNTK
MNTK Risk / Return Rank: 1616
Overall Rank
MNTK Sharpe Ratio Rank: 1717
Sharpe Ratio Rank
MNTK Sortino Ratio Rank: 2020
Sortino Ratio Rank
MNTK Omega Ratio Rank: 2121
Omega Ratio Rank
MNTK Calmar Ratio Rank: 1414
Calmar Ratio Rank
MNTK Martin Ratio Rank: 99
Martin Ratio Rank

BEAM
BEAM Risk / Return Rank: 5252
Overall Rank
BEAM Sharpe Ratio Rank: 5353
Sharpe Ratio Rank
BEAM Sortino Ratio Rank: 5757
Sortino Ratio Rank
BEAM Omega Ratio Rank: 5454
Omega Ratio Rank
BEAM Calmar Ratio Rank: 4747
Calmar Ratio Rank
BEAM Martin Ratio Rank: 4747
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

MNTK vs. BEAM - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Montauk Renewables, Inc. (MNTK) and Beam Therapeutics Inc. (BEAM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


MNTKBEAMDifference

Sharpe ratio

Return per unit of total volatility

-0.54

0.29

-0.83

Sortino ratio

Return per unit of downside risk

-0.47

1.03

-1.51

Omega ratio

Gain probability vs. loss probability

0.95

1.12

-0.17

Calmar ratio

Return relative to maximum drawdown

-0.77

0.19

-0.96

Martin ratio

Return relative to average drawdown

-1.52

0.42

-1.95

MNTK vs. BEAM - Sharpe Ratio Comparison

The current MNTK Sharpe Ratio is -0.54, which is lower than the BEAM Sharpe Ratio of 0.29. The chart below compares the historical Sharpe Ratios of MNTK and BEAM, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading graphics...

Sharpe Ratios by Period


MNTKBEAMDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

-0.54

0.29

-0.83

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.52

-0.29

-0.24

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.49

0.05

-0.54

Correlation

The correlation between MNTK and BEAM is 0.30, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Dividends

MNTK vs. BEAM - Dividend Comparison

Neither MNTK nor BEAM has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

MNTK vs. BEAM - Drawdown Comparison

The maximum MNTK drawdown since its inception was -94.49%, which is greater than BEAM's maximum drawdown of -89.12%. Use the drawdown chart below to compare losses from any high point for MNTK and BEAM.


Loading graphics...

Drawdown Indicators


MNTKBEAMDifference

Max Drawdown

Largest peak-to-trough decline

-94.49%

-89.12%

-5.37%

Max Drawdown (1Y)

Largest decline over 1 year

-58.67%

-38.15%

-20.52%

Max Drawdown (5Y)

Largest decline over 5 years

-94.49%

-89.12%

-5.37%

Current Drawdown

Current decline from peak

-94.34%

-82.16%

-12.18%

Average Drawdown

Average peak-to-trough decline

-56.06%

-59.29%

+3.23%

Ulcer Index

Depth and duration of drawdowns from previous peaks

29.50%

17.33%

+12.17%

Volatility

MNTK vs. BEAM - Volatility Comparison

Montauk Renewables, Inc. (MNTK) has a higher volatility of 20.72% compared to Beam Therapeutics Inc. (BEAM) at 17.93%. This indicates that MNTK's price experiences larger fluctuations and is considered to be riskier than BEAM based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading graphics...

Volatility by Period


MNTKBEAMDifference

Volatility (1M)

Calculated over the trailing 1-month period

20.72%

17.93%

+2.79%

Volatility (6M)

Calculated over the trailing 6-month period

57.94%

53.97%

+3.97%

Volatility (1Y)

Calculated over the trailing 1-year period

82.88%

78.23%

+4.65%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

72.31%

75.45%

-3.14%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

73.42%

80.57%

-7.15%

Financials

MNTK vs. BEAM - Financials Comparison

This section allows you to compare key financial metrics between Montauk Renewables, Inc. and Beam Therapeutics Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0050.00M100.00M150.00M200.00M250.00M300.00M350.00MAprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober
306.72M
0
(MNTK) Total Revenue
(BEAM) Total Revenue
Values in USD except per share items